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Objectives: The risk of dying by alcohol-specific causes in people with epilepsy has
seldom been reported from population-based studies. We aimed to estimate the relative
risk of alcohol-specific mortality in people with epilepsy, and the extent to which
problematic alcohol use was previously identified in the patients’ medical records.
Method: We delineated cohort studies in two population-based datasets, the Clinical
Practice Research Datalink (CPRD GOLD) in England (January 01, 2001–December
31, 2014) and the Secure Anonymised Information Linkage (SAIL) Databank in Wales
(January 01, 2001–December 31, 2014), linked to hospitalization and mortality records.
People with epilepsy were matched to up to 20 persons without epilepsy on gender,
age (±2 years) and registered general practice. We identified alcohol-specific death from
Office for National Statistics (ONS) records using specified ICD-10 codes. We further
identified prescriptions, interventions and hospitalisations related to alcohol use.
Results: In the CPRD GOLD, we identified 9,871 individuals in the incident epilepsy
cohort and 185,800 in the comparison cohort and, in the SAIL Databank, these
numbers were 5,569 and 110,021, respectively. We identified a five-fold increased risk
of alcohol-specific mortality in people with epilepsy vs. those without the condition
in our pooled estimate across the two datasets (deprivation-adjusted HR 4.85,
95%CI 3.46–6.79).
Conclusions: People with epilepsy are at increased risk of dying by an alcohol-specific
cause than those without the disorder. It is plausible that serious alcohol misuse could
either contribute to the development of epilepsy or it could commence subsequent to
epilepsy being diagnosed. Regardless of the direction of the association, it is important
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that the risk of dying as a consequence of alcohol misuse is accurately quantified in
people affected by epilepsy. Systematically-applied, sensitive assessment of alcohol
consumption by healthcare professionals, at opportunistic, clinical contacts, with rapid
access to quality treatment services, should bemandatory and play a key role in reduction
of health harms and mortality.
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INTRODUCTION
People with epilepsy are known to die prematurely compared to
the rest of the general population (1, 2). However, the need for
improved identification of specific causes of death, and associated
risks of these deaths in people with epilepsy has been recognized.
Devinsky et al. suggest that the contribution of alcohol to death
in people with epilepsy may be underestimated (2). Recently, we
reported that people with epilepsy were three-times more likely
to die from unnatural causes than those without (3). Whilst we
did not study alcohol-specific mortality, we noted the greater
frequency of alcohol misuse in people with epilepsy (6.0%) vs. the
comparison cohort (1.4%). This warranted further investigation.
Death due to alcohol-dependence syndrome in people with
epilepsy was associated with a standardized mortality rate of
3.9 (95% CI 1.8–7.4) in a prevalent epilepsy cohort identified
from attendees at an Austrian epilepsy hospital clinic (4). In
2016, of the 137,000 epilepsy deaths and 14.7 million epilepsy
Disability-adjusted life years (DALYs) in the United Kingdom,
an estimated 17,000 epilepsy deaths and 1.5 million epilepsy
DALYs were attributed to alcohol, representing 12.7% of all
deaths and 10.2% of all DALYs due to epilepsy (5). Alcohol-
related death is a wide definition that may include end-
organ disease attributed to alcohol (6). To our knowledge,
the only published study that specifically examines alcohol-
related death in people with epilepsy is a Finnish register-
based cohort in which people with epilepsy were compared
to a population-based reference cohort. A three-fold elevation
in risk of death due to alcohol-related diseases and accidental
poisoning by alcohol was observed (HR 3.38, 95%CI 2.76–
4.16) (7). These deaths were identified by certain codes from
the International Classification of Diseases and Related Health
Problems, ninth and tenth editions (ICD-9, ICD-10). The specific
ICD-10 codes used have some parallels with, but are not
identical to those which the Office for National Statistics (ONS)
in the UK identified as alcohol-related deaths in the UK
until 2016 in official death statistics (6). In 2017, the ONS
replaced the definition for alcohol-related death with one for
alcohol-specific death, in response to an expert consultation.
To our knowledge, this is the first study to utilize this new
categorization to examine the risk of alcohol-specific death in
people with epilepsy.
The aims of this study were therefore to (i) estimate the
incidence and relative risk of alcohol-specific death in people
with epilepsy vs. persons without the condition; and (ii) estimate
the extent of alcohol-related consultation, treatment or referral in
relation to epilepsy status and alcohol-related death.
MATERIALS AND METHODS
Data Source
We examined the Clinical Practice Research Datalink (CPRD
GOLD), an electronic healthcare dataset which comprises general
practice data from 7% of the UK population (8). It includes
demographic, diagnostic, prescription, referral and test data
from individuals in registered practices; and is considered to
be broadly representative of the UK population as a whole
in terms of its age, gender and ethnicity distributions. We
defined our study populations from a subset of practices that
were linked to Hospital Episode Statistics (HES) and Office for
National Statistics (ONS) data; all of which were in England
and represented ∼58% of all practices in the CPRD. The HES
provides hospital discharge dates and diagnoses whilst ONS
provides date and causes of death (8). We extracted the incident
epilepsy and matched cohorts from the July 2015 release of the
CPRD which included 7,378,852 patients from 387 practices
in England with routine data linkage implemented. We also
estimated the incidence rates and relative risks of alcohol-
specific death in the Secure Anonymised Information Linkage
(SAIL) Databank, which enabled meta-analysis of relative risk
estimates across two independent datasets. The SAIL Databank
is comprised of 13 health and social care datasets. These include
the general practice dataset (GPD) which contains similar data
to the CPRD and includes 76% of all general practices in Wales
(practice n = 360, patients n = 4,052,388) (9). ONS death data
is detailed within the Annual District Death Extract (ADDE) and
hospital discharge dates and diagnoses are included in the Patient
Episode Database for Wales (PEDW) (10). As the CPRD cohort
only included practices in England, there was no overlap with
those individuals in the SAIL Databank. Approvals to conduct
these studies in the CPRD and the SAIL Databank were granted
by the Independent Scientific Advisory Committee (ISAC) of the
Medicine and Healthcare Regulatory Agency (MHRA) (protocol
15_046RA2R) and the Information Governance Review Panel
(approval 0728), respectively.
Delineation of the Matched-Cohort
Epilepsy diagnoses were identified from the general practice
data in the CPRD and the SAIL Databank using Read codes,
version 2 (11). Separately in each dataset, we identified people
as having incident epilepsy if they had the first evidence of a
code for epilepsy diagnosis and an associated prescription for an
antiepileptic drug (AED) in the month before or 6 months after
the diagnosis. The requirement for both an epilepsy diagnosis
and AED treatment is suggested to increase the reliability of
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TABLE 1 | Reproduced from Office for National Statistics.
ICD-10 Code Condition
E24.4 Alcohol-induced pseudo-Cushing’s syndrome
F10 Mental and behavioral disorders due to use of alcohol





K70 Alcoholic liver disease
K85.2 Alcohol-induced acute pancreatitis
K86.0 Alcohol induced chronic pancreatitis
Q86.0 Fetal alcohol syndrome (dysmorphic)
R78.0 Excess alcohol blood levels
X45 Accidental poisoning by and exposure to alcohol
X65 Intentional self-poisoning by and exposure to alcohol
Y15 Poisoning by and exposure to alcohol, undetermined intent
Alcohol-specific deaths in the UK: registered in 2016. Newport: Office for National
Statistics; 2016.
the ascertainment of epilepsy in observational studies, by the
International League Against Epilepsy (ILAE) (12) and is a
definition we have previously applied in epidemiological studies
of epilepsy (13). The use of primary care records in the SAIL
Databank to identify people with epilepsy has been validated
(14). The codes used to identify epilepsy diagnoses and AEDs,
and an explanation of the verification process, are available on
www.clinicalcodes.org (15). A minimum age of 18 years on study
entry was imposed to align with theminimum legal age of alcohol
purchase in the UK. Individuals were also required to have at least
1 year of prior registration in the practice, during which time they
could not have had a diagnosis of epilepsy. This increased our
confidence that we had delineated an incident epilepsy cohort.
We defined the study period as January 1, 2001–March 31, 2014
in the CPRD and January 1, 2001–December 31, 2014 in the SAIL
Databank, to correspond with linkage availability.
We matched each individual with epilepsy to up to 20
individuals without an epilepsy diagnosis on year of birth (±2
years), gender and general practice. Individuals were eligible for
inclusion in the comparison cohort if they had at least 1 year of
prior registration in the general practice and were alive on the
index epilepsy date of the matched individual with epilepsy, and
follow-up began on this date. Individuals were followed until the
earliest date of: death, patient left practice, end of data collection
in the practice, or the final observation date for the study cohort.
Identification of Alcohol-Specific Mortality
We used the ONS definition of alcohol-specific mortality,
which was introduced in 2017 to replace the previous
definition of alcohol-related mortality, following a UK
government consultation with leading experts in the field
(6). It includes underlying cause of death codes assigned from
the ICD-10 (Table 1).
Statistical Analysis
We used descriptive statistics to report baseline characteristics
of age, gender and area-level deprivation. We estimated alcohol-
specific mortality rate per 10,000 person-years and the risk
of alcohol-specific mortality as a hazard ratio (HR), using
stratified Cox-proportional hazards models to account for the
matched cohort design. We report estimates separately based
on the CPRD and the SAIL Databank data, and meta-analyzed
estimates using the DerSimonian-Laird Random Effects model
(16). To better understand whether alcohol consumption had
been acknowledged in primary or secondary care records prior
to death in those who died by alcohol-specific causes, we
estimated the proportion of individuals who were: (i) coded as
a heavy drinker; (ii) received a prescription for acamprosate,
disulfiram, nalmefene or naltrexone for alcohol dependence;
(iii) referred for psychological support for alcohol use and
(iv) hospital admission for alcohol-related causes; in relation
to their epilepsy status. We used codes and algorithms that
were previously published to define these variables (17), and
they are available on www.clinicalcodes.org.uk (15). Alcohol
consumption was defined in relation to the national guidance




We matched 9,871 people with incident epilepsy with 185,800
individuals in the comparison cohort in the CPRD (Table 2).
The median age on entry was 57 (IQR 39–73) in the
epilepsy cohort and 58 (IQR 40–74) in the comparison cohort
and 51% of both cohorts were male. The epilepsy cohort
was followed-up for a median of 3.2 years (1.2–6.6) whilst
the comparison cohort was followed-up for a median of
4.3 years (1.9–7.7). 9.7% of people in the epilepsy cohort
and 6.4% in the comparison cohort were categorized as
being a “heavy drinker.” Death due to any cause was a
more common reason for end of follow-up in the epilepsy
cohort (23.1%) than in the comparison cohort (11%). The
distribution of covariates was similar in the analysis conducted
in the SAIL Databank, which included 5,569 people with
incident epilepsy and 110,021 people in the comparison
cohort (Table 2).
Risk of Alcohol-Specific Mortality in
People With Epilepsy
There were 29 alcohol-specific deaths in the incident epilepsy
cohort and 106 in the comparison cohort in the CPRD, and the
corresponding numbers were 18 and 96 in the SAIL Databank,
respectively. The deprivation-adjusted hazard ratios for alcohol-
specific mortality in people with epilepsy vs. those without were
5.47 (95%CI 3.52–8.48) in the CPRD and 4.08 (95%CI 2.42–6.90)
in the SAIL Databank, and the pooled estimate was 4.85 (95%CI
3.46–6.79) (Table 3).
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TABLE 2 | Baseline characteristics of epilepsy and comparison cohorts in the CPRD and SAIL databank.
CPRD SAIL








Male 5,062 (51·3%) 95,647 (51.5%) 2,874 (51.6%) 56,729 (51.6%)
Median age on entry (IQR) 57 (39–73) 58 (40–74) 54 (37–70) 54 (37–70)
Level of deprivationa
1 (least deprived) 1,908 (19.3%) 40,105 (21.5%) 905 (16.3%) 21,022 (19.1%)
2 2,190 (22.2%) 43,077 (23.2%) 928 (16.7%) 20,186 (18.4%)
3 1,870 (18.9%) 37,066 (20.0%) 1,248 (22.4%) 24,158 (22.0%)
4 1,959 (19.9%) 35,257 (19.0%) 1,204 (21.6%) 22,714 (20.7%)
5 (most deprived) 1,937 (19.6%) 30,111 (16.2%) 1,280 (23.0%) 21,776 (19.8%)
missing 7 (0.1%) 184 (0.1%) <5 (0.1%) 165 (0.2%)
Follow up
Median follow-up time (years) 3.2 (1.2–6.6) 4.3 (1.9–7.7) 4.7 (IQR 1.8–8.6) 5.9 (IQR 2.6–9.7)
Alcohol consumptionb,c
Non-drinker 1,774 (18.0%) 26,360 (14.2%)
Former drinker 315 (3.2%) 2,772 (1.5%)
Occasional drinker 1,248 (12.6%) 24,087 (13.0%)
Moderate drinker 3,359 (34.0%) 74,782 (40.3%)
Heavy drinker 958 (9.7%) 11,881 (6.4%)
Missing 2,217 (22.5%) 45,968 (24.6%)
Data on alcohol consumption could only be calculated in the CPRD. aBased-on quintiles of multiple deprivation where 1 is the most deprived and 5 is the least deprived. bAlcohol
consumption status estimated at index date based on algorithm by Parisi et al. (17). cP < 0.001. The black shaded portion represents that the descriptive analysis was not conducted
in the SAIL Databank.








HR (95% CI) Deprivation-adjusted HR
(95%CI)
CPRD Epilepsy cohort
(n = 9,871; PY = 41,253)
Comparison cohort
(n = 185,800; PY = 916,572)
29 7.0 (4.7–10.1) 106 1.2 (0.9–1.4) 6.09 (3.96–9.37) 5.47 (3.52–8.48)
SAIL Epilepsy cohort
(n = 5,569; PY = 30,011)
Comparison cohort
(n = 110,021; PY = 685,575)
18 6.0 (3.6–9.5) 96 1.4 (1.1–1.7) 4.40 (2.62–7.37) 4.08 (2.42–6.90)
Meta-analyzed hazard ratios 5.33 (3.83–7.42) 4.85 (3.46–6.79)
Alcohol Consumption and Alcohol-Related
Diagnoses, Treatment, Psychological
Support and Hospitalization
Amongst those in the CPRD who died due to alcohol specific
causes, compared to the matched cohort, a greater proportion
of people with epilepsy had medication prescribed for alcohol
dependence (24.1 vs. 9.3%; p = 0.03). There were proportionally
more people in the epilepsy cohort than the comparison cohort
who were referred for psychological support for alcohol use,
but this was not statistically significant (20.7 vs. 11.3%; P =
0.19). There was no statistically significant difference between
coding as a “heavy drinker” at any time prior to death in the
epilepsy and comparison cohorts in the CPRD (79.3 vs. 67.0%;
p = 0.2). A similar proportion of each group had ever been
hospitalized for reasons related to alcohol use (84.9 vs. 86.2%).
A greater proportion of the epilepsy cohort than the comparison
cohort had a history of alcohol misuse, as determined by any
of these indicators, prior to index date (i.e., prior to epilepsy
diagnosis), but this difference was not statistically significant
(79.3 vs. 72.6%; p= 0.47).
DISCUSSION
Elevated Risk of Alcohol-Specific Death
Wehave shown across two, large population-based cohort studies
that people with epilepsy are approximately five times more
likely to die from alcohol-specific causes than persons without
the condition (deprivation-adjusted meta-analyzed HR: 4.85,
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95%CI 3.46–6.79). Of those people who died from alcohol-
specific causes, the majority had a hospital admission that was
attributed to alcoholism (epilepsy cohort: 86.2%; comparison
cohort: 84.9%). Many were coded as being a heavy drinker in
primary care records, but fewer were prescribed medication for
alcohol or received psychological support. Still, alcohol misuse
had not been coded in primary care records prior to death in 20
to 28% of people. For those individuals whose alcohol misuse has
been identified in primary care or due to previous hospitalization,
thought should be given as to how to maximize these contact
opportunities to try to prevent the sequel of events that culminate
in hospitalization and premature death.
Our estimate of relative risk of dying by an alcohol-specific
cause in people with epilepsy is of a greater magnitude than
that predicted by Nevalainen et al. (HR 4.85, 95%CI 3.46–6.79
compared to 3.44, 95%CI 3.11–3.71) from Finnish mortality
records. That study’s somewhat lower estimate could be a
reflection in differences in habits in population drinking habits
or access to healthcare in Finland, England and Wales. Estimates
of per capita alcohol consumption in 2016 were higher in the
UK (11.4 L/capita) than Finland (10.7 L/capita) (19). It may
also be a function of study design. We used a more recent
time period than the 2008 study-end in the Finnish study. We
both used ICD-10 codes to define the outcome, but the Finnish
study reported alcohol-related deaths whereas we report alcohol-
specific deaths. In some aspects we were broader; for example
inclusion of intentional poisoning with alcohol, whereas the
Finnish investigators included only accidental poisoning (7). In
other aspects, the previous study employed broader codes, for
example, “Special epilepsy syndromes” of which alcohol is one
potential cause. In a systematic review of systematic reviews,
alcohol involvement was identified as a high risk cause of alcohol-
related mortality (20).
Other studies have reported the proportion or likelihood of
alcohol involvement in death among persons with epilepsy. The
National Drug-Related Deaths Index of Ireland is a surveillance
system that records all causes of death in people who are
dependent on alcohol or drugs, or die due to poisoning (21).
Two percent of individuals in this register were known to have
epilepsy and 81% of these had a history of alcohol dependence
prior to death. In a nested case-control study conducted in
the General Practice Research Database (the predecessor to the
CPRD), Risdale et al. (22) identified that amongst people with
epilepsy, those who died during follow-up were more likely to
have a record of alcohol misuse (OR 2.96, 95%CI 2.25–3.89) than
those who did not die. Our study design does not permit us
to compare to these estimates. It does, however highlight that
alcohol misuse have been identified as a major contributor to
premature death in people with epilepsy. We have not found any
literature that maps primary care recording of alcohol misuse
prior to alcohol-specific death in people with epilepsy.
In the UK General Practice Survey, there was a three-fold
increased risk of death (HR 2.9, 95%CI 1.5–5.7) if alcohol was
a cause of epilepsy compared to if it was not (23). In a meta-
analysis of studies, a relative risk of 2.19 (95%CI 1.83–2.63)
was estimated for epilepsy or unprovoked seizures in relation
to alcohol consumption, and a dose-dependent relationship was
evident (24). Consuming 12, 48, 72, and 96 g/day of alcohol was
associated with relative risk increases, vs. non-drinkers, of 1.2
(95%CI; 1.1–1.2), 1.8 (95% CI 1.6–2.1), 2.4 (2.0, 3.0) and 3.3
(95%CI 2.5–4.3), respectively (25). One confounder in studies has
been the difficulty in distinguishing between alcohol-withdrawal
and non-withdrawal seizures.
A two-fold increased risk in Sudden Unexpected Death in
Epilepsy (SUDEP) has been associated with alcohol dependence
(26). This is not recorded in the datasets we used. Our findings
must be interpreted with the important caveat that pre-existing
alcohol dependence may have caused seizures or epilepsy in
some cases. Alcohol has been suggested to be responsible for
1/20–1/5 of Disability-adjusted Life Years in people with epilepsy
(27). The great majority of individuals in the epilepsy cohort
(∼80%) had codes for non-specific epilepsy. It was therefore
not possible to determine whether seizures were classified
as alcohol-induced. Our use of the incident epilepsy cohort
somewhat overcomes this limitation by allowing us to identify
the first epilepsy diagnosis and therefore understand whether
any history of alcohol misuse or dependence was identified
before or after this diagnosis. However, it is possible that alcohol
dependence occurs some time before diagnosis, treatment
or psychological intervention was recorded in the general
practice data.
Strengths and Limitations
To our knowledge, this is the first study to estimate the
relative risk of death specific to alcohol misuse in those with
epilepsy across two large population-based databases and to
pool the estimates to optimize statistical precision. We have
applied the most up-to-date definition of alcohol-specific death
that is now being used in routine mortality registration in
England & Wales (6). This will enable any recommendations
that we make to be implemented and measured against this
standard definition in future years. We report for the first time
estimates for primary care identification of alcohol misuse or
dependence prior to alcohol-specific death in a matched epilepsy
and comparison cohort.
We could not stratify by type of epilepsy or seizure frequency
due to limitations in recording, nor could we report relative
risk for each individual alcohol-specific cause. This is due to
the low numbers of death at this more granular analytical level,
which could not be reported without compromising anonymity,
and that would produce imprecise relative risk estimates. The
availability of self-reported alcohol consumption data in the
CPRD is likely to be incomplete, and may not be entirely
accurate, influenced by the individual’s willingness to accurately
report alcohol use and opportunity to record this information,
such as during primary care consultations. Given that alcohol
misuse and dependence can induce seizures, whether the primary
cause of epilepsy or not, it might be expected that people
with epilepsy would have their alcohol status recorded more
so than those people in our comparison cohort. This could
artificially widen the gap in reporting. There should be no
differential misclassification between the groups for prescription
or psychological referral recording.
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Implications for Clinicians
Regardless of the direction of the association between epilepsy
and alcohol misuse, clinicians should be mindful of the large
elevation in risk of alcohol-specific death among people with
epilepsy. Any progress toward stopping drinking alcohol can
have a beneficial effect on survival of people with alcohol-
related cirrhosis (28). Given the magnitude of the risk elevation
observed, it is important that clinicians who are treating people
with epilepsy are aware of alcohol misuse. This might enable
targeted intervention and person-centered holistic care, both of
which have been recommended to enhance the care for people
with alcohol-related diseases (29). Indeed, exploration of alcohol
use in people with epilepsy is recommended through use of the
“SUDEP and seizure safety” checklist in the UK (30). Additional,
candid discussions about level of alcohol use at the point of
epilepsy diagnosis and at regular reviews could be warranted. It
should be noted that, in the same study cohort, the incidence of
alcohol-specific death is lower than we previously observed for
other potentially preventable causes of mortality, such as accident
and suicide (3). However, the considerable morbidity related to
alcohol-induced seizures in epilepsy, whether this was the initial
cause or not, supports the need to discuss the impact of alcohol
misuse among epilepsy. Indeed, the observed difference in rate
might reflect the immediacy that may be related to accident
or suicide, whereas many of the alcohol-specific causes are a
culmination over time.
The historical, global stigmatization of people with epilepsy
(31) or alcohol problems, of particular concern when the two
co-exist, can lead to denied or delayed acceptance, presentation,
detection, treatment and health risks, including death, from the
two conditions. The commonality of concurrent mental illness
in people with epilepsy and the independent increased risk of
accident (32), suicide (33), and alcohol use related to mental
illness should not be ignored. Upstream identification, treatment
and management of mental illness in people with epilepsy has
the potential to mitigate preventable causes of death, a priority
described in the 2016 Call to Action on this issue (2).
CONCLUSION
We have observed a five-fold elevated risk of alcohol-specific
deaths in people with epilepsy compared to those without. Many
but not all of those who died had a hospitalization or primary
care event signifying excessive alcohol use. Hence, in people with
epilepsy, systematically-applied, sensitive assessment of alcohol
consumption (34) by healthcare professionals, at opportunistic,
clinical contacts, with rapid access to quality treatment services,
should be mandatory and play a key role in reduction of health
harms and mortality.
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